Management of chronic hepatitis C in French departments of internal medicine and infectious diseases

Epidemiology and Infection

Volumn 133, Issue 2, 2005, Pages 305-314

  Cacoub, Patrice ^a,i   Goderel, I ^b   Morlat, P ^c,i   Sene, D ^a   Myers, R P ^a   Alric, L ^d,i   Loustaud Ratti, V ^e   Melin, P ^f,i   Limal, N ^a,i   Ouzan, D ^g   Perronne, C ^h   Carrat, F ^b   Amir, A ⁱ   Andre, P ⁱ   Arlaund, J ⁱ   Arsac, P ⁱ   Baglioni, R ⁱ   Bazin, C ⁱ   Bentata, M ⁱ   Bernard, N ⁱ   Bielefeld, A ⁱ   Blanc, F ⁱ   Boissonnas, A ⁱ   Boitard, C ⁱ   Bosseray, A ⁱ   Brogard, J M ⁱ   Brunel, M ⁱ   Buu Sao, A ⁱ   Cabane, J ⁱ   Capron, D ⁱ   Cassuto, J P ⁱ   Cathebras, P ⁱ   Chemlal, K ⁱ   Cohen, P ⁱ   Couland, J P ⁱ   Cuzin, L ⁱ   Delfraissy, J F ⁱ   Dellamonica, P ⁱ   Demolombre, S ⁱ   Di Martino, V ⁱ   Durand, J M ⁱ   Faller, J P ⁱ   Fantin, B ⁱ   Faucherre, V ⁱ   Fur, A ⁱ   Galanaud, P ⁱ   Garre, M ⁱ   Gefray, L ⁱ   Gil, H ⁱ   Ginsburg, C ⁱ   Goichot, B ⁱ   Goujard, C ⁱ   Grasset, D ⁱ   Guillevin, L ⁱ   Halfon, P ⁱ   Jarrousse, B ⁱ   Jaussaud, R ⁱ   Joliot, Y ⁱ   Karmochkine, M ⁱ   Le Moing, V ⁱ   Le Quellec, A ⁱ   Leport, C ⁱ   Libbre, E ⁱ   Lunel Fabiani, F ⁱ   Marchou, B ⁱ   May, T ⁱ   Meyohas, M C ⁱ   Michelet, C ⁱ   Moussali, J ⁱ   Mouton, Y ⁱ   Ninet, J ⁱ   Opolon, P ⁱ   Piroth, L ⁱ   Portier, H ⁱ   Poynard, T ⁱ   Raguin, G ⁱ   Remy, G ⁱ   Rosenthal, E ⁱ   Perre, P ⁱ   Piette, J C ⁱ   Rozenbaum, W ⁱ   Rucher, H ⁱ   Salmon Ceron, D ⁱ   Sicard, D ^i,i   Sogni, P ⁱ   Schlienger, J L ⁱ   Schmit, J L ⁱ   Sereni, D ⁱ   Serfati, L ⁱ   Series, C ⁱ   Trepo, C ⁱ   Vallerno, A J ⁱ   VIlde, J L ⁱ   Vittecoq, D ⁱ   Wahl, D ⁱ   Warnet, A ⁱ   Wemeau, J ⁱ   Yeni, P ⁱ   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

^d CHU PURPAN   (France)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f HÔPITAL DU BOCAGE   (France)

^g INSTITUT ARNAULT TZANCK   (France)

^h RAYMOND POINCARÉ HOSPITAL   (France)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; CRYOGLOBULINEMIA; DATA ANALYSIS; DRUG ABUSE; FEMALE; FRANCE; GENERAL CONDITION IMPROVEMENT; GENOTYPE; HEPATITIS C; HOSPITAL DEPARTMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INTERNAL MEDICINE; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; SUPERINFECTION;

ADULT; ANTIVIRAL AGENTS; BIOPSY; FEMALE; FRANCE; GENOTYPE; HEPATITIS B, CHRONIC; HIV INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; INTERNAL MEDICINE; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 20144389122     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268804003486     Document Type: Article

References (36)

1. Lauer GM, Walker BD. Hepatitis C virus infection. New Engl J Med 2001; 345: 41-52.
2. Dubois F, Desenclos J, Mariotte N, Goudeau A. Hepatitis C in a French population based survey, 1994, distribution and risk factors. Hepatology 1997; 25: 1490-1496.
3. Deuffic-Burban S, Wong JB, Valleron AJ, Costagliola D, Delfraissy JF, Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 2004; 40 319-326.
4. Cacoub P, Raguin G, Veyssier P, et al. Hepatitis C virus infection in internal medicine and infectious diseases departments in France. Preliminary results of a national epidemiological survey [in French]. Presse Med 1996; 25: 349-352.
5. Raguin G, Rosenthal E, Cacoub P, et al. Hepatitis C in France: a national survey in the departments of internal medicine and infectious diseases. Eur J Epidemiol 1998; 14: 545-548.
6. Myers RP, Regimbeau C, Thevenot T, et al. Interferon for chronic hepatitis C (Cochrane Review). Cochrane Database Syst Rev 2002: CD000370
7. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
8. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31: 211-218.
9. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
10. Fried MW, Shiffman ML, Reddy KR, et al. Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
11. EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999; 30: 956-961.
12. Conférence de Consensus Française sur le Traitement de l'Hépatite C - Textes des experts. How to treat hepatitis C? [in French]. Gastroenterol Clin Biol 2002; 26: B313-B320.
13. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002-10-12 June 2002. Hepatology 2002; 36: S3-S20.
14. Goegebeur G, Benhamiche AM, Minello A, et al. The characteristics of patients with hepatitis C virus antibodies followed in specialized university hospital units are different from those of patients in the general population. The Research Group of the REBOHC [in French]. Gastroenterol Clin Biol 2000; 24: 1042-1046.
15. Frère T, Verneau A, Besson I, et al. Treatment of hepatitis C virus infection in the Poitou-Charentes region [in French]. Gastroenterol Clin Biol 1999; 23: 887-891.
16. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D and the Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6664 patients. Hepatology 1997; 26: 485-490.
17. Roudot-Thoraval F. Modifications of epidemiological characteristics of hepatitis C [in French]. Gastroenterol Clin Biol. 2002; 26 (Spec. no. 2): B138-143.
18. Dhumeaux D. Hepatitis C in France [in French] Gastroenterol Clin Biol 2002; 26 (Spec. no. 2): B133-137.
19. Roudot-Thoraval F. Modifications of epidemiological characteristics of hepatitis. Gastroenterol Clin Biol 2002; 26: B138-143.
20. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. Medicine 2000; 79: 47-56.
21. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 1999; 42: 2204-2212.
22. Cacoub P, Lidove O, Maisonobe T, et al. Interferon alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002; 46: 3317-3326.
23. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acq Immune Defic Syndr 2000; 24: 211-217.
24. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001; 32: 492-497.
25. Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G. Mortality among HIV-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis virus C in French departments of Internal Medicine/Infectious Diseases in 1995 and 1997. Clin Infect Dis 2001; 32: 1207-1214.
26. Soriano V, Martin-Carbonero L, Puoti M, Garcia-Samaniego J. Mortality due to chronic viral liver disease in HIV-infected patients. Clin Infect Dis 2001; 33: 1793-1794.
27. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16: 813-828.
28. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. Hepatology 1999; 30: 1054-1058.
29. Rosenthal E, Poirée M, Pradalier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 1803-1809.
30. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136: 288-292.
31. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001; 345: 215-217.
32. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345: 211-214.
33. Chung R, Andersen J, Volberding P, et al. PEG-interferon-alfa-2a plus ribavirin versus interferon-alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-co-infected persons. N Engl J Med 2004; 351: 451-459.
34. Torriani FJ, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon-alfa-2a plus ribavirin versus interferon-alfa-2a plus ribavirin in HIV-infected patients. N Engl J Med 2004; 351: 438-450.
35. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. J Am Med Assoc 2004; 292: 2839-2848.
36. Laguno M, Murillas J, Blanco JL, et al. Peginterferon-alfa-2b plus ribavirin versus interferon-alfa-2b plus ribavirin for treetment of HIV-HCV co-infected patients. AIDS 2004; 18 F27-F36.